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Botulinum toxin type A (BoNT-A) has been reported as an effective treatment for 
chronic migraine. When BoNT-A is injected on the frontalis muscle for chronic 
migraine, an unexpected clinical side effect called the “Mephisto sign” may occur. 
The aim of this article is to propose a method to eliminate or prevent the Mephisto 
sign side effect. A 25-year-old female patient visited the hospital and was diag-
nosed with chronic migraine. A total of 155 U of BoNT-A was injected into 31 
sites. 2-weeks later, and the patient developed the Mephisto sign. An additional 
2-U dose was administered bilaterally to the lateral-most point of the frontalis 
muscles, and the eyebrow morphology returned to normal within 2-3 weeks. We 
propose that the development of the Mephisto sign may be prevented with an ad-
ditional BoNT-A injection of 2-4 U bilaterally to the lateral most point of the fron-
talis muscles during the primary injection process.
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INTRODUCTION
Botulinum toxin type A (BoNT-A) has been used to treat many diseases, including 
strabismus, blepharospasm, dystonia, glabella wrinkle, hyperhidrosis and cerebral 
palsy. In 2010, the United States Food and Drug Administration approved the use 
of BoNT-A (BOTOX, Allergan, Irvine, CA, USA) to prevent chronic migraine in 
adult patients, and it emerged as a second choice of treatment for chronic migraine 
patients who did not respond to the existing pharmacotherapy. The approval was 
made based on the double-blind, randomized, placebo-controlled phases of the 
Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMT) clinical 
program.1,2
BoNT-A injection has been reported as an effective treatment for chronic mi-
graine. According to Blumenfeld, et al.,3 a minimum of 155 U of BoNT-A is recom-
mended for chronic migraine to be injected in a total of 31 sites. It has been report-
ed that 5 U each of BoNT-A should be injected in 4 sites of the frontalis muscle. 
The medial injection sites are located at a point with an invisible line drawn up 
about 1.5 cm from the medial end of the eyebrow from the corrugator injection site. 
The lateral injection sites are about 1.5 cm lateral and parallel to the medial injec-
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via an additional injection of BoNT-A at the 2-week follow-
up appointment. It is quite likely that the additional injection 
paralyzed the lateral fibers of the frontalis muscle that were 
not fully paralyzed earlier, thereby evenly reducing muscle 
tone on the entire frontalis muscle and resulting in an even 
location maintenance of eyebrow morphology. While the 
Mephisto sign may be relieved by an additional injection, it 
might also be prevented entirely by simply adding this pro-
cedure during the primary injection, taking into account the 
underlying anatomy. When injecting BoNT-A at the four 
predetermined sites in the frontalis muscle, 2 to 4 U of ad-
ditional BoNT-A injection at the lateral-most point of the 
frontalis muscle (Fig. 2) will paralyze the frontalis muscle 
fully,6 thus preventing the appearance of the Mephisto sign. 
A detailed and accurate knowledge of the anatomy of the 
muscles that raise and lower the eyebrows is important for 
predicting the interaction between the muscles after BoNT-
A injection in chronic migraine. The probability of the oc-
currence of the Mephisto sign may vary depending on the 
length, structure and morphology of the frontalis muscle 
and injection skills of clinician. Nevertheless, it is difficult 
to predict the chances of outbreak. 
If the Mephisto sign occurs, it is likely that patients devel-
op troubles in social life because of negative impression 
which may lead to poor relationship between clinicians and 
tions sites explained previously. 
When BoNT-A is injected to treat chronic migraine, an 
unexpected clinical side effect may occur. The “Mephisto 
sign” may develop as a side effect of BoNT-A injection into 
the frontalis muscle, whereby the outer end of the eyebrow 
is located above the inner end, possibly producing an intimi-
dating impression. It is also referred to as a “quizzical look”, 
“Spock’s eyebrow”, “a sinister look” or “‘joker’ face”.4 Al-
though temporary, this is a concerning result for both clini-
cians and patients, since the effect may last for at least 3 
months.
 CASE REPORT
 
A 25-year-old female patient visited the hospital due to fre-
quent headaches, and was diagnosed with chronic mi-
graine. There was no specific medical history. She did not 
effectively respond to various types of pharmacotherapy, 
and BoNT-A injection was indicated. BoNT-A injections 
were performed as described above, so that a total of 155 U 
was injected into 31 sites. At the follow-up appointment 2 
weeks later, the patient reported a change in eyebrow mor-
phology, showing the Mephisto sign. An additional BoNT-
A dose of 2 U each was administered to the lateral-most 
point of the frontalis muscle bilaterally. However, the mor-
phology of eyebrow became normalized within 2-3 weeks 
after this additional injection.
DISCUSSION
As described herein, when BoNT-A is injected to the original 
sites proposed for chronic migraine, a side effect may occur 
in eyebrow morphology. After injection, the distal ends of the 
eyebrows-which are normally positioned below the height 
of the eyebrow contour (Fig. 1A)-become raised so that 
they are in a more superior position compared to the rest of 
the eyebrow, pointing upwards, forming the Mephisto sign 
(Fig. 1B). This condition occurs when the lateral fibers of 
the frontalis muscles, which raise eyebrows, are not suffi-
ciently paralyzed compared to the medial fibers. Consequent-
ly, the inner end of the eyebrow falls and the outer end rais-
es because of paralysis of the medial fibers and hyperactivity 
of the lateral fibers, resulting in brow malposition to make a 
hook shape.4,5 
In the case described herein, this condition was relieved 
Fig. 2. Proposed injection points of BoNT-A on the frontalis muscle in 
chronic migraine, with additional injection points marked in red. BoNT-A, 
botulinum toxin type A.
Fig. 1. (A) Before BoNT-A injection, (B) 2 weeks after BoNT-A injection. 
BoNT-A, botulinum toxin type A.
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patients. An additional BoNT-A injection at a later date on 
the position mentioned above may improve the eyebrow, 
however, unsettling the trust issues. It is also uneconomical, 
considering additional visit of the patients and a need to open 
an additional new bottle of BoNT-A and using only 2 to 4 U. 
A well-controlled research with a larger number of sub-
jects to confirm the benefit/risk ratio of the injection is need-
ed. Nevertheless, an additional injection using the leftover 
BoNT-A during the primary injection for chronic migraine 
is expected to be efficient, prevents the side effects and causes 
minimum additional discomfort to patients. On the other 
hand, occurrence of risk factors of an additional injection 
including eyebrow ptosis, eyelid ptosis and upper eyelid 
swelling should be more accurately estimated. 
In conclusion, we propose this simple method to prevent 
the Mephisto sign after BoNT-A injection for chronic mi-
graine: injection of an additional 2-4 U of BoNT-A into the 
distal end of the frontalis muscle either prophylactically at 
the primary injection, or at the follow-up appointment if nec-
essary. This is a proposal based on our own limited experi-
ences, and further well-designed studies are required to con-
firm its efficacy. 
